LONDON (TheStreet) -- An experimental rheumatoid arthritis pill from AstraZeneca (AZN) and Rigel (RIGL) produced mixed results in a late-stage clinical trial, raising additional questions about the drug's future.
In the study known as OSKIRA-1, two doses of fostamatinib significantly improved the signs and symptoms of rheumatoid arthritis compared to a placebo following 24 weeks of treatment. However, fostamatinib failed to show improvements over placebo in bone erosion and joint-space narrowing as measured by X-ray.
The most common adverse events reported in the study included hypertension, diarrhea, nausea, headache and cold symptoms. Detailed safety data was not disclosed, but in previous studies, fostamatinib was shown to cause high blood pressure.
AstraZeneca has been counting on fostamatinib to boost revenue at a time when many of its existing drugs are losing out to cheaper generic alternatives. The mixed results from the OSKIRA-1 study announced Friday will likely be viewed as another setback for the drug.Last December, a mid-stage study showed fostamatinib to be inferior to Abbvie's (ABBV) Humira. Pfizer (PFE) has also recently launched its own rheumatoid arthritis pill, Xejanz. AstraZeneca is conducting two additional phase III studies of fostamatinib, with results expected later this quarter. AstraZeneca licensed the drug from Rigel in 2010. Shares of AstraZeneca were trading slightly lower in London. Rigel closed Thursday at $7.53, ahead of the fostamatinib trial results. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV